Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1974 Oct 12;4(5936):91-92, 93-94. doi: 10.1136/bmj.4.5936.91

Variability in Response to Drugs*

Michael D Rawlins
PMCID: PMC1612144  PMID: 4607336

Abstract

Variability in the response to drugs is due to three principal components—the disease, the responsiveness of tissues, and the concentration of the drug at its site of action (as reflected by its plasma concentration). The relative contributions of these components will differ not only for different drugs but also for different effects of the same drug. Rational drug therapy depends on knowledge of all three factors.

Full text

PDF
91

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARMSTRONG A. R., PEART H. E. A comparison between the behavior of Eskimos and non-Eskimos to the administration of isoniazid. Am Rev Respir Dis. 1960 Apr;81:588–594. doi: 10.1164/arrd.1960.81.4.588. [DOI] [PubMed] [Google Scholar]
  2. Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121–134. doi: 10.1002/cpt1970111121. [DOI] [PubMed] [Google Scholar]
  3. Asberg M., Crönholm B., Sjöqvist F., Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J. 1971 Aug 7;3(5770):331–334. doi: 10.1136/bmj.3.5770.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BUCHTHAL F., SVENSMARK O., SCHILLER P. J. Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. Arch Neurol. 1960 Jun;2:624–630. doi: 10.1001/archneur.1960.03840120030004. [DOI] [PubMed] [Google Scholar]
  5. Beller G. A., Smith T. W., Abelmann W. H., Haber E., Hood W. B., Jr Digitalis intoxication. A prospective clinical study with serum level correlations. N Engl J Med. 1971 May 6;284(18):989–997. doi: 10.1056/NEJM197105062841801. [DOI] [PubMed] [Google Scholar]
  6. Bertler A., Redfors A. Plasma levels of digoxin in relation to toxicity. Acta Pharmacol Toxicol (Copenh) 1971;29 (Suppl 3):281–287. doi: 10.1111/j.1600-0773.1971.tb03307.x. [DOI] [PubMed] [Google Scholar]
  7. Bertler A., Smith S. E. Genetic influences in drug responses of the eye and the heart. Clin Sci. 1971 May;40(5):403–410. doi: 10.1042/cs0400403. [DOI] [PubMed] [Google Scholar]
  8. Black D. A., Rose G., Brewer D. B. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J. 1970 Aug 22;3(5720):421–426. doi: 10.1136/bmj.3.5720.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Borgå O., Azarnoff D. L., Forshell G. P., Sjöqvist F. Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol. 1969 Sep;18(9):2135–2143. doi: 10.1016/0006-2952(69)90318-9. [DOI] [PubMed] [Google Scholar]
  10. CAWEIN M., BEHLEN C. H., 2nd, LAPPAT E. J., COHN J. E. HEREDITARY DIAPHORASE DEFICIENCY AND METHEMOGLOBINEMIA. Arch Intern Med. 1964 Apr;113:578–585. doi: 10.1001/archinte.1964.00280100086014. [DOI] [PubMed] [Google Scholar]
  11. CRANSTON W. I., JUEL-JENSEN B. E. The effects of spironolactone and chlorthalidone on arterial pressure. Lancet. 1962 Jun 2;1(7240):1161–1164. doi: 10.1016/s0140-6736(62)92199-2. [DOI] [PubMed] [Google Scholar]
  12. Cullhed I. Hemodynamic effects of lidocaine. Acta Med Scand. 1969 Jul-Aug;186(1-2):53–55. doi: 10.1111/j.0954-6820.1969.tb01438.x. [DOI] [PubMed] [Google Scholar]
  13. DEVADATTA S., GANGADHARAM P. R., ANDREWS R. H., FOX W., RAMAKRISHNAN C. V., SELKON J. B., VELU S. Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960;23:587–598. [PMC free article] [PubMed] [Google Scholar]
  14. EVANS D. A., DAVISON K., PRATT R. T. THE INFLUENCE OF ACETYLATOR PHENOTYPE ON THE EFFECTS OF TREATING DEPRESSION WITH PHENELZINE. Clin Pharmacol Ther. 1965 Jul-Aug;6:430–435. doi: 10.1002/cpt196564430. [DOI] [PubMed] [Google Scholar]
  15. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Finnerty F. A., Jr, Davidov M., Kakaviatos N. Hypertensive vascular disease. The long term effect of rapid repeated reductions of arterial pressure with diazoxide. Am J Cardiol. 1967 Mar;19(3):377–384. doi: 10.1016/0002-9149(67)90451-1. [DOI] [PubMed] [Google Scholar]
  17. Furniss P. The etiology of malignant hyperpyrexia. Proc R Soc Med. 1971 Feb;64(2):216–220. [PMC free article] [PubMed] [Google Scholar]
  18. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  19. Grahame-Smith D. G. Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J. 1969 Feb 1;1(5639):286–289. doi: 10.1136/bmj.1.5639.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hammar C. G., Alexanderson B., Holmstedt B., Sjöqvist F. Gas chromatography-mass spectrometry of nortriptyline in body fluids of man. Clin Pharmacol Ther. 1971 May-Jun;12(3):496–505. doi: 10.1002/cpt1971123496. [DOI] [PubMed] [Google Scholar]
  21. Hammer W., Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. 1967 Sep 1;6(17):1895–1903. doi: 10.1016/0024-3205(67)90218-4. [DOI] [PubMed] [Google Scholar]
  22. Hanngren A., Borgå O., Sjöqvist F. Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS). Scand J Respir Dis. 1970;51(1):61–69. [PubMed] [Google Scholar]
  23. Jenne J. W., Wyze M. S., Rood F. S., MacDonald F. M. Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline. Clin Pharmacol Ther. 1972 May-Jun;13(3):349–360. doi: 10.1002/cpt1972133349. [DOI] [PubMed] [Google Scholar]
  24. Johnstone E. C., Marsh W. The relationship between response to phenelzine and acetylator status in depressed patients. Proc R Soc Med. 1973 Sep;66(9):947–949. doi: 10.1177/003591577306600959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Koch-Weser J., Klein S. W., Foo-Canto L. L., Kastor J. A., DeSanctis R. W. Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. N Engl J Med. 1969 Dec 4;281(23):1253–1260. doi: 10.1056/NEJM196912042812301. [DOI] [PubMed] [Google Scholar]
  26. Kutt H., McDowell F. Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients. JAMA. 1968 Mar 11;203(11):969–972. [PubMed] [Google Scholar]
  27. LOESER E. W., Jr Studies on the metabolism of diphenylhydantoin (Dilantin). Neurology. 1961 May;11:424–429. doi: 10.1212/wnl.11.5.424. [DOI] [PubMed] [Google Scholar]
  28. Lewis R. J., Trager W. F. The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci. 1971 Jul 6;179:205–212. doi: 10.1111/j.1749-6632.1971.tb46900.x. [DOI] [PubMed] [Google Scholar]
  29. Lund L., Lunde P. K., Rane A., Borga O., Sjöqvist F. Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man. Ann N Y Acad Sci. 1971 Jul 6;179:723–728. doi: 10.1111/j.1749-6632.1971.tb46947.x. [DOI] [PubMed] [Google Scholar]
  30. Manninen V., Korhonen A. Letter: Inequal digoxin tablets. Lancet. 1973 Dec 1;2(7840):1268–1268. doi: 10.1016/s0140-6736(73)91011-8. [DOI] [PubMed] [Google Scholar]
  31. Manninen V., Melin J., Reissel P. Tablet disintegration: possible link with biological availability of digoxin. Lancet. 1972 Feb 26;1(7748):490–491. doi: 10.1016/s0140-6736(72)90146-8. [DOI] [PubMed] [Google Scholar]
  32. Mroczek W. J., Leibel B. A., Davidov M., Finnerty F. A., Jr The importance of the rapid administration of diazoxide in accelerated hypertension. N Engl J Med. 1971 Sep 9;285(11):603–606. doi: 10.1056/NEJM197109092851104. [DOI] [PubMed] [Google Scholar]
  33. O'REILLY R. A., AGGELER P. M., HOAG M. S., LEONG L. S., KROPATKIN M. L. HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED. N Engl J Med. 1964 Oct 15;271:809–815. doi: 10.1056/NEJM196410152711602. [DOI] [PubMed] [Google Scholar]
  34. PRANKERD T. A. ENZYMES AND DRUG SENSITIVITY. GLUCOSE 6-PHOSPHATE DEHYDROGENASE DEFICIENCY. Proc R Soc Med. 1964 Jun;57:506–508. doi: 10.1177/003591576405700626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sjöqvist F. A pharmacokinetic approach to the treatment of depression. Int Pharmacopsychiatry. 1971;6(3):147–169. doi: 10.1159/000468267. [DOI] [PubMed] [Google Scholar]
  36. Smith S. E., Rawlins M. D. Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol. Eur J Clin Pharmacol. 1974;7(1):71–75. doi: 10.1007/BF00614394. [DOI] [PubMed] [Google Scholar]
  37. Wagner J. G., Northam J. I., Alway C. D., Carpenter O. S. Blood levels of drug at the equilibrium state after multiple dosing. Nature. 1965 Sep 18;207(5003):1301–1302. doi: 10.1038/2071301a0. [DOI] [PubMed] [Google Scholar]
  38. White T. A., Evans D. A. The actylation of sulamethazine and sulfamethoxypyridazine by human subjects. Clin Pharmacol Ther. 1968 Jan-Feb;9(1):80–88. doi: 10.1002/cpt19689180. [DOI] [PubMed] [Google Scholar]
  39. Zacest R., Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther. 1972 May-Jun;13(3):420–425. doi: 10.1002/cpt1972133420. [DOI] [PubMed] [Google Scholar]
  40. de Matteis F. Disturbances of liver porphyrin metabolism caused by drugs. Pharmacol Rev. 1967 Dec;19(4):523–557. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES